SGLT2 inhibitors are recommended for people with type 2 diabetes and chronic kidney disease to slow CKD progression and reduce albuminuria, benefits that extend beyond glucose lowering [106, 115, 116]. Here, SLC5A2 is linked to type 2 diabetes mellitus.